In conclusion, although the combination of lapatinib and vinorelbine was tolerable, it did not demonstrate added clinical benefits compared with single-agent chemotherapy vinorelbine in metastatic HER2-positive breast cancer patients when used beyond the second line after patient progression on trastuzumab and lapatinib. The gene discussed is ERBB2; the disease is breast carcinoma.